1. Design and Synthesis of a Phenyl C-Glycoside Derivative of Spliceostatin A and its Biological Evaluation toward Prostate Cancer Treatment.Yoshikawa Y, Ishibashi A, Murai K, Kaneda Y, Nimura K(corresponding author), Arisawa M.Tetrahedron Letters. 2019 Dec 19; 60(51):151313. doi.org/10.1016/j.tetlet.2019.151313
2. NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis. Saga K, Park J, Nimura K, Kawamura N, Ishibashi A, Nonomura N, Kaneda Y.J Exp Clin Cancer Res. 2019 Oct 16;38(1):416. doi:10.1186/s13046-019-1429-z.
3. SF3B2-mediated RNA splicing drives human prostate cancer progression.Kawamura N*, Nimura K*(corresponding author), Saga K, Ishibashi A, Kitamura K, Nagano H, Yoshikawa Y, Ishida K, Nonomura N, Arisawa M, Luo J, Kaneda Y. (*co-first)Cancer Res. 2019 Oct 15;79(20):5204-5217. doi: 10.1158/0008-5472.CAN-18-3965. Epub 2019 Aug 20.
4. Tai JA, Chang CY, Nishikawa T, Kaneda Y.Cancer immunotherapy using the Fusion gene of Sendai virus. Cancer Gene Ther. 2019 Aug 6. doi: 10.1038/s41417-019-0126-6.
5. Fujita K, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M, Imamura R, Okihara K, Ukimura O, Miki T, Nakajima T, Kaneda Y, Nonomura N., Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer., Cancer Sci. 2020 Feb 29. doi: 10.1111/cas.14366.
6. Kiyohara E, Tanemura A, Nishioka M, Yamada M, Tanaka A, Yokomi A, Saito A, Sakura K, Nakajima T, Myoui A, Sakurai T, Kawakami Y, Kaneda Y, Katayama I., Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study., Cancer Immunol Immunother. 2020 Feb 11. doi: 10.1007/s00262-020-02509-8.